Brief: Cognition Therapeutics Presents Complete EEG Findings From Sequel Study Of CT1812 In Mild-To-Moderate Alzheimer's Disease At CTAD
24/10/2023 22:14
Oct 24 (Reuters) - Cognition Therapeutics Inc CGTX.O :
* COGNITION THERAPEUTICS PRESENTS COMPLETE EEG FINDINGS FROM
SEQUEL STUDY OF CT1812 IN MILD-TO-MODERATE ALZHEIMER’S DISEASE
AT CTAD
* COGNITION - CT1812 TREATMENT SHOWED IMPROVEMENT OF EEG
PARAMETERS THAT ARE CONSISTENT IN MAGNITUDE AND EFFECT SIZE WITH
PREVIOUSLY REPORTED TRIALS
Source text for Eikon: ID:nGNX8GVqzg
Further company coverage: CGTX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB